Oral GLP-1 at Med Spas 2026: Foundayo, Oral Semaglutide & What Operators Must Know

For three years, "GLP-1 at a med spa" has meant one thing: a weekly injection. Whether it was branded Wegovy and Zepbound or compounded semaglutide and tirzepatide during the shortage years, the delivery was always a needle in a pen or a vial-and-syringe. In 2026 that changed. The FDA has now approved the first oral GLP-1 medications for weight loss, and for the first time operators can offer a credible pill-based track inside a program that until now was injectable-only.

This is genuinely new ground. The oral options behave differently from injectables on efficacy, titration, tolerability, and — critically for your business model — on sourcing and margin. They also come with a hard rule that catches a lot of operators off guard: there is no legal compounded oral GLP-1. This guide walks through exactly what the oral options are, who they're for, how to prescribe them compliantly, and how to bolt an oral track onto an existing weight-loss program without creating new liability. For the underlying regulatory framework that applies to all GLP-1 therapy, read it alongside our GLP-1 med spa compliance complete guide, which this post is designed to extend rather than repeat.

The 2026 Oral GLP-1 Arrival — Why It Matters for Med Spas

The arrival of oral GLP-1 is not a minor product update. It removes the single biggest barrier that has kept a meaningful slice of the weight-loss market out of your chair: the needle. Survey after survey has shown that a real percentage of people who would benefit from GLP-1 therapy decline it specifically because they will not self-inject. An oral option converts some of those people from "never" to "maybe."

From needle-only to a pill option

Until late 2025, every GLP-1 weight-loss medication on the market was a subcutaneous injection. The mechanism that made these drugs work — long-acting peptides that mimic the GLP-1 hormone — also made them difficult to deliver as pills, because peptides are broken down in the gut. Two different scientific approaches solved that problem in two different ways, which is why we now have two oral products that look similar to patients but are quite different under the hood. Understanding that difference is what lets you counsel patients honestly and price each option correctly.

What changed in late 2025 and 2026

Two approvals defined the shift. In December 2025, the FDA approved oral semaglutide 25 mg — the "Wegovy pill" — as the first oral GLP-1 indicated for chronic weight management. Then in April 2026, the FDA approved Foundayo (orforglipron), Eli Lilly's once-daily small-molecule GLP-1, which made headlines because it can be taken any time of day with no food or water restrictions. Together they signal that the obesity-medication market is moving from an injectable-only category to one where patients will increasingly expect to be offered a choice of route. For a med spa, "we only do injections" is starting to sound dated.

Why this is a demand event, not just a clinical one

From a practice-growth standpoint, the oral launch is a demand event. It expands the addressable pool of weight-loss patients, it gives you a new reason to re-engage leads who previously balked, and it creates a natural "step-up / step-down" conversation that keeps patients in your program longer. But the same launch is also a compliance event, because a new route of administration does not come with a new, looser set of rules. Everything you already do for injectable GLP-1 — the Good Faith Exam, individualized prescribing, monitoring, documentation, medical director sign-off — carries straight over. The operators who win with orals will be the ones who treat them as a serious clinical service, not a convenience add-on.

Foundayo (Orforglipron): What It Is and How It Works

Foundayo is the brand name for orforglipron, Eli Lilly's once-daily oral GLP-1 receptor agonist, approved by the FDA on April 1, 2026 for adults with obesity, or overweight with at least one weight-related comorbidity. It is the headline product of the oral era because of one design feature: unlike oral semaglutide, it does not require an empty stomach, a water limit, or a waiting period before eating.

How orforglipron works as a small molecule

The key distinction is chemical. Semaglutide — injectable or oral — is a peptide. Orforglipron is a small-molecule GLP-1 receptor agonist, which means it is built more like a conventional pill drug than like a fragile peptide. That matters for two practical reasons. First, it is far more stable in the digestive tract, so it does not need the absorption-enhancing workarounds and rigid timing that oral semaglutide requires. Second, small-molecule manufacturing scales differently from peptide manufacturing, which the manufacturer has positioned as an advantage for long-term supply. For patients, the headline benefit is simple: a pill you can take with your coffee, on a full or empty stomach, morning or night.

Foundayo dosing and titration

Like all GLP-1 medications, Foundayo is titrated upward gradually to manage gastrointestinal side effects. Patients start at a low dose and step up over a period of weeks toward a maintenance dose, with the highest studied dose producing the strongest weight-loss results. In pivotal trials, top-dose orforglipron produced roughly 11% mean body-weight reduction — equivalent to around 27 pounds for many participants — with a substantial share of patients reaching at least 10% weight loss. That is a clinically meaningful result that sits below top-dose injectable tirzepatide but is squarely in useful territory, and the convenience of a flexible-timing pill is a real adherence advantage. As with any titration schedule, your SOP should specify the dose steps, the minimum interval between increases, and the criteria for pausing or holding a step-up when a patient is struggling with side effects.

Access and cash price

Foundayo launched with manufacturer-direct availability and broad pharmacy distribution. Self-pay patients can access entry doses starting around $149 per month, and eligible commercially insured patients may pay substantially less through the manufacturer savings program. For a med spa, the important takeaway is that the drug itself carries a published, fixed price the patient pays to the manufacturer or pharmacy — it is not a product you buy at wholesale and resell at a spread. That single fact reshapes the margin conversation, which we cover below.

Oral Semaglutide: The Wegovy Pill

The Wegovy pill is oral semaglutide dosed at 25 mg for weight management, approved in December 2025 as the first oral GLP-1 for weight loss. It is the same molecule as injectable Wegovy, reformulated to survive oral delivery — and that reformulation is exactly why it comes with strict instructions.

How oral semaglutide differs from the injection

Because semaglutide is a peptide, getting it absorbed through the stomach lining requires an absorption enhancer and very specific conditions. The result is a pill that works on the same mechanism as the familiar injection but with a different dosing experience. In the OASIS 4 trial, oral semaglutide 25 mg produced about 16.6% mean weight loss at 64 weeks with full adherence — strong numbers that approach injectable semaglutide territory, with the explicit caveat that "full adherence" matters a great deal for a peptide pill whose absorption depends on the patient following the rules precisely. Unlike the injection, the pill does not require refrigeration, which is a genuine convenience for travel and storage.

The strict dosing window patients must follow

This is where patient education becomes a compliance issue, not just a courtesy. Oral semaglutide must be taken in the morning, on an empty stomach, with no more than about four ounces of plain water, and the patient must wait roughly 30 minutes before eating, drinking anything else, or taking other oral medications. Skip the rules and absorption — and therefore efficacy — drops. For a med spa, this means your consent and patient-education materials for oral semaglutide must spell out the dosing window explicitly, and your follow-up visits should confirm the patient is actually taking it correctly. A patient who is "not responding" may simply be taking the pill with breakfast. Foundayo's lack of timing restrictions is precisely what differentiates it for patients who know they will not reliably follow a 30-minute fasted window.

When the pill is the right semaglutide

Oral semaglutide is a natural fit for a patient who responded well to, or is curious about, semaglutide specifically but wants to avoid the weekly injection, and who is disciplined enough to follow the morning fasted routine. It is also a reasonable maintenance option for a patient stepping down from a higher-intensity injectable regimen. The clinical decision of which molecule and which route belongs in the Good Faith Exam and the provider's note — not in a pricing menu.

Oral vs Injectable GLP-1 — Efficacy, Tolerability, Adherence

The single most useful thing you can do for patients is to be honest about the trade-offs. Orals are not "the same as injections but easier." They are a different point on the curve, and the right framing is that they trade some peak potency for convenience and a lower barrier to starting.

Efficacy: where orals land vs injectable tirzepatide

Here is the honest hierarchy as of mid-2026. Injectable tirzepatide remains the efficacy leader, producing roughly 21% mean body-weight reduction at top dose over about 88 weeks in its pivotal program. Injectable semaglutide sits around 15%. Among the orals, oral semaglutide 25 mg reached about 16.6% at 64 weeks with full adherence, and orforglipron produced roughly 11% at its highest dose. So the orals are meaningful — an 11% to 16% reduction is life-changing for most patients — but the ceiling is generally below top-dose injectable tirzepatide. A patient whose goal is maximum weight loss should hear that an injectable, particularly tirzepatide, is still the most potent tool. For the clinical detail on the injectable side, see our tirzepatide protocol guide and our GLP-1 injection protocol.

GI tolerability and titration

All GLP-1 medications share the same dominant side-effect profile: nausea, constipation, diarrhea, and reduced appetite, most pronounced during dose escalation. Orals are not exempt — they are titrated slowly for exactly this reason. There is no strong evidence that the oral route eliminates GI effects; the side-effect burden is driven by the mechanism, not the delivery. What the oral route does change is the patient's ability to manage their experience: a pill is easy to hold or delay a step-up without the "I already injected it" finality of a weekly pen. Your titration SOP and your nausea-management guidance should apply to oral patients just as they do to injectable patients.

Adherence — the needle-averse advantage

Adherence is where orals genuinely shine, and it is the strongest reason to offer them. A meaningful number of patients will start an oral who would never have started an injection. No needles, no sharps disposal, no refrigeration for the pills, and — in Foundayo's case — no rigid timing window. For these patients the relevant comparison is not "oral versus injectable," it is "oral versus nothing at all," and on that comparison the oral wins every time. The counterpoint is real-world adherence to the dosing rules: oral semaglutide's efficacy depends on the fasted-morning routine, so an oral is only as good as the patient's consistency. Setting expectations honestly at the Good Faith Exam protects both the patient's results and your practice's reputation.

Who Is the Right Candidate for Oral GLP-1

Candidate selection is a clinical decision, made during the Good Faith Exam and documented in the provider's note. It is not a marketing default, and it is not "whatever the patient saw on TikTok." That said, there are clear patterns for who tends to do well on an oral.

Needle-averse and early-stage patients

The clearest oral candidate is the patient who would otherwise decline GLP-1 therapy entirely because of the needle. Close behind are patients with lower-to-moderate weight-loss targets, patients who want to "try the class" with a lower psychological commitment before considering an injectable, and frequent travelers who don't want to manage refrigerated, dated pens through airport security and hotel mini-fridges. For these patients an oral is not a compromise — it is the option that actually gets them into treatment.

When an injectable is still the better call

Be equally clear about who should still be on an injection. Patients seeking maximum weight loss, those with higher starting BMIs and aggressive goals, and patients who have plateaued on an oral are all better served by an injectable — most potently by tirzepatide. A patient who has already tolerated injections well and is hitting their targets has little reason to switch routes. The "step-up" conversation — moving a patient from an oral to an injectable when the oral plateaus — is a legitimate and valuable part of a mature program, and it should be framed as a clinical escalation, documented accordingly, not as an upsell.

Contraindications that don't change with route

The contraindications and cautions for GLP-1 therapy apply regardless of route. A personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, a history of pancreatitis, certain gastrointestinal conditions, pregnancy, and relevant drug interactions all need to be screened at intake exactly as they are for injectables. The pill format does not soften the screening. Your intake and GFE workflow should treat an oral GLP-1 request with the same diligence as an injectable request.

Prescribing, Good Faith Exam, and Scope of Practice for Oral GLP-1

This is the section operators most want to skip and most need to read. An oral GLP-1 is a prescription medication. Everything that makes injectable GLP-1 a regulated medical service applies identically to the pill. The route changes the patient experience; it does not change the law.

The Good Faith Exam still applies

Before any oral GLP-1 prescription is issued, a licensed provider must perform a Good Faith Exam — evaluating the patient, reviewing history and contraindications, establishing medical necessity, and documenting the clinical rationale for the specific medication and route chosen. This is non-negotiable and is the same standard you already apply to injectable GLP-1. A common and dangerous shortcut is to treat an oral as "just a pill" that can be added to an existing injectable patient without a fresh decision. Switching a patient from an injectable to an oral, or starting an oral de novo, is a prescribing decision that deserves its own documented note. Our weight-loss injections compliance guide covers the GFE and documentation expectations in depth, and all of it carries over to orals.

Scope of practice and the NP/PA question

Who may prescribe an oral GLP-1 is governed by the same state scope-of-practice rules as any prescription weight-loss medication. In full-practice-authority states, a nurse practitioner may evaluate, prescribe, and manage oral GLP-1 therapy independently within their scope. In reduced- or restricted-practice states, the NP must operate under a collaborative or supervisory agreement, and a physician assistant always prescribes under a supervising physician. Estheticians and unlicensed staff cannot prescribe, period — and cannot perform the GFE. The oral route does not expand anyone's scope. If your team could prescribe injectable GLP-1, the same people can prescribe the oral under the same conditions; if they couldn't, they still can't.

Medical director oversight

Your medical director's role does not shrink because the medication is a pill. The MD should review and sign the oral GLP-1 SOP, the consent forms, and the monitoring protocol, exactly as for injectables. Standing orders, chart-review cadence, adverse-event escalation, and protocol review all extend to the oral track. If you are unclear on what your medical director is actually responsible for, our med spa medical director requirements guide lays it out by function. Adding orals is a good trigger to confirm your MD arrangement covers the new service in writing.

Sourcing and the No-Compounded-Oral Reality

This is the single most important compliance message in this entire guide, so it gets its own section: there is no legal compounded oral GLP-1. If you take nothing else away, take that.

Branded-only — there is no legal compounded oral GLP-1

The compounded GLP-1 market that exploded from 2022 onward existed because injectable semaglutide and tirzepatide were on the FDA's official shortage list, which temporarily permitted 503A and 503B pharmacies to compound those molecules. That window has largely closed for injectables, and the FDA has moved to keep these molecules off the 503B bulk-drug list — see the FDA's proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The oral products never had a shortage declaration at all. Oral semaglutide and orforglipron are patented, branded, FDA-approved products with no compounding pathway whatsoever. Any "compounded oral semaglutide," sublingual GLP-1 drop, or oral GLP-1 troche on the market is operating outside an FDA-approved oral pathway.

Sourcing channels and what to avoid

For oral GLP-1, the legitimate channels are the branded products obtained through normal pharmacy distribution and the manufacturers' direct programs. Your patient gets a genuine, FDA-approved product; your practice provides the medical management around it. Avoid any vendor pitching a compounded, sublingual, or "research-grade" oral GLP-1 — the cost savings are illusory and the liability is severe. Dispensing or directing patients to a non-approved oral product exposes your medical director's license, your facility, and your malpractice coverage to exactly the kind of risk that ends practices. If a deal on "oral GLP-1 powder" looks too good to be true, it is, and it is almost certainly not legal. Confirm sourcing against current FDA guidance at fda.gov, and follow AmSpa's medical weight-loss guidance at americanmedspa.org.

What the branded-only reality means for your model

Because you can't compound the orals, you can't build margin on a cheap drug spread the way some practices did with compounded injectables. That is not a bug — it is a feature for a compliance-first practice. It pushes your business model toward what it should have been all along: charging for clinical care, not for a markup on a vial. The clinical-review review summary "From needles to pills: oral GLP-1 therapy enters the obesity arena" is a useful primer on where the oral class fits clinically.

Pricing, Margin, and Cash-Pay Dynamics

The oral launch forces a healthier pricing conversation. With a fixed, published branded price, the old compounded-injectable playbook — buy low, mark up the vial — simply doesn't apply. Here is how to think about it.

Why oral margin math differs from compounded injectables

During the compounded era, the drug itself might cost a practice a small fraction of what the patient paid, and the margin lived in that spread. Branded orals invert this. The patient pays roughly $149 per month (at entry doses) to the manufacturer or pharmacy for the medication, and that price is visible and fixed. You are not buying inventory and reselling it. So if you try to bury a markup inside a branded price, two things happen: the patient can see the manufacturer price online, and you create a transparency problem. The margin has to come from somewhere else — and the right place is the medical service.

Building a defensible cash-pay price

Price the oral track as a clinical program. A defensible structure charges for the Good Faith Exam, the initial labs and review, ongoing monitoring visits, provider time, and the convenience of managed care — while the patient obtains the branded medication through the manufacturer or pharmacy. Many practices set a monthly or quarterly program fee that covers the visit cadence and oversight, separate from the cost of the drug. This is cleaner, more defensible, and more durable than a drug markup: it is honest, it survives price transparency, and it reflects the actual value you provide, which is medical management and accountability, not pill distribution. It also aligns your incentives with the patient's outcomes rather than with how much medication they consume.

Positioning orals alongside injectables on your menu

Offer both routes and let the clinical conversation decide. A simple, honest menu might present an injectable track and an oral track at similar program-fee levels, with the medication cost disclosed separately for each. This positions your practice as a medical weight-loss provider that offers the full toolkit, rather than a reseller of one product. It also makes the step-up and step-down conversations natural: a patient can start oral and escalate to injectable, or maintain on oral after an injectable phase, all within one program and one relationship.

How to Add an Oral GLP-1 Track to Your Weight-Loss Program

If you already run an injectable GLP-1 program, adding orals is an extension, not a rebuild. The clinical and compliance scaffolding you have should expand to cover the new route.

Updating SOPs and consent for orals

Start with documentation. Your GLP-1 SOP needs an oral section covering each approved oral product, its dosing and titration schedule, the specific administration instructions (especially oral semaglutide's fasted-morning window), monitoring requirements, and adverse-event management. Your informed-consent forms need oral-specific versions that disclose the realistic efficacy range, the side-effect profile, the dosing rules, and the honest comparison to injectables. Get all of it reviewed and signed by your medical director before you prescribe the first oral. If your operational foundation needs work, our operations and compliance resources cover the intake, consent, and oversight documents that wrap around any clinical service.

Patient education and the switch conversation

Build patient-education materials that set honest expectations: what the pill can realistically deliver, how to take it correctly, what side effects to expect during titration, and when to call. For existing injectable patients curious about switching, create a structured "switch conversation" that is documented as a clinical decision — covering why the patient wants to change, whether the change serves their goals, and what the new plan is. Don't let a route change happen casually at the front desk. Equally, train your team to recognize when an oral patient should be stepped up to an injectable rather than left to plateau.

Monitoring and follow-up cadence

Oral patients need the same monitoring discipline as injectable patients: scheduled follow-ups, weight and tolerability checks, labs as clinically indicated, and documentation at every touchpoint. For oral semaglutide specifically, use follow-ups to verify the patient is taking the medication correctly — a surprising number of "non-responders" are simply taking the pill with food. Treat adherence verification as part of the clinical visit, not an afterthought.

Common Mistakes Operators Make Adding Oral GLP-1

The oral category is new enough that the same avoidable errors are showing up across practices. Here are the ones to watch for.

Treating orals like compounded injectables

The most expensive mistake is assuming the compounded playbook transfers. It does not. There is no compounded oral GLP-1, so any attempt to source a cheap "compounded oral" is sourcing an illegal or non-approved product. And the margin model is different — there is no vial spread to capture. Operators who try to run orals like the compounded era either expose themselves to enforcement risk or build a pricing structure that collapses the moment a patient checks the manufacturer's website. Internalize the branded-only reality and price for the service.

Skimping on the GFE and monitoring

Because a pill feels lower-stakes than an injection, some practices quietly relax the Good Faith Exam, the contraindication screening, or the follow-up cadence for oral patients. This is a serious error. The medication is the same class with the same risk profile, the same contraindications, and the same prescribing requirements. A relaxed standard for orals is exactly the kind of inconsistency a plaintiff's attorney or a medical board investigator will seize on. Hold the oral track to the identical clinical standard as the injectable track.

Over-promising efficacy and ignoring scope

Two more traps. First, marketing the orals as equivalent to top-dose injectable tirzepatide sets patients up for disappointment and sets you up for complaints — be honest that orals generally deliver somewhat less peak weight loss. Second, assuming the pill lets non-prescribers "handle" weight-loss patients. Scope of practice is unchanged: only a provider authorized to prescribe in your state can prescribe the oral, and only after a GFE. If you wouldn't let a given staff member prescribe an injectable, they can't prescribe the pill either. A weight-loss program that respects both honest efficacy framing and scope-of-practice limits is the one that lasts. For practices building or strengthening their hormone and metabolic service lines alongside weight loss, our 2026 hormone therapy compliance guide covers the adjacent compliance terrain.